Subanalysis of a prospective , 12-month , multicenter , phase IIIb trial ( Efficacy and Safety of Ranibizumab in Patients with Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration [ EXCITE ] ) .